Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Filters applied: . Clear all
Page 1
Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study.
McClung MR, O'Donoghue ML, Papapoulos SE, Bone H, Langdahl B, Saag KG, Reid IR, Kiel DP, Cavallari I, Bonaca MP, Wiviott SD, de Villiers T, Ling X, Lippuner K, Nakamura T, Reginster JY, Rodriguez-Portales JA, Roux C, Zanchetta J, Zerbini CAF, Park JG, Im K, Cange A, Grip LT, Heyden N, DaSilva C, Cohn D, Massaad R, Scott BB, Verbruggen N, Gurner D, Miller DL, Blair ML, Polis AB, Stoch SA, Santora A, Lombardi A, Leung AT, Kaufman KD, Sabatine MS; LOFT Investigators. McClung MR, et al. Lancet Diabetes Endocrinol. 2019 Dec;7(12):899-911. doi: 10.1016/S2213-8587(19)30346-8. Epub 2019 Oct 31. Lancet Diabetes Endocrinol. 2019. PMID: 31676222 Clinical Trial.
We aimed to investigate the efficacy and safety of odanacatib to reduce fracture risk in postmenopausal women with osteoporosis. METHODS: The Long-term Odanacatib Fracture Trial (LOFT) was a multicentre, randomised, double-blind, placebo-controlled, event-driven study at 3 …
We aimed to investigate the efficacy and safety of odanacatib to reduce fracture risk in postmenopausal women with osteoporosis. METHODS: Th …
New developments in the treatment of osteoporosis.
Eriksen EF, Halse J, Moen MH. Eriksen EF, et al. Among authors: halse j. Acta Obstet Gynecol Scand. 2013 Jun;92(6):620-36. doi: 10.1111/j.1600-0412.2012.01473.x. Acta Obstet Gynecol Scand. 2013. PMID: 22646526 Free article. Review.
In younger postmenopausal women, low-dose estrogen or estrogen/progestin still has a place for short-term (up to 5 years) preservation of bone mass, especially in women with menopausal symptoms. ...
In younger postmenopausal women, low-dose estrogen or estrogen/progestin still has a place for short-term (up to 5 years) preservatio …
Six months supplementation with conjugated linoleic acid induces regional-specific fat mass decreases in overweight and obese.
Gaullier JM, Halse J, Høivik HO, Høye K, Syvertsen C, Nurminiemi M, Hassfeld C, Einerhand A, O'Shea M, Gudmundsen O. Gaullier JM, et al. Among authors: halse j. Br J Nutr. 2007 Mar;97(3):550-60. doi: 10.1017/S0007114507381324. Br J Nutr. 2007. PMID: 17313718 Clinical Trial.
Long-term supplementation with conjugated linoleic acid (CLA) reduces body fat mass (BFM) and increases or maintains lean body mass (LBM). ...
Long-term supplementation with conjugated linoleic acid (CLA) reduces body fat mass (BFM) and increases or maintains lean body mass ( …
Supplementation with conjugated linoleic acid for 24 months is well tolerated by and reduces body fat mass in healthy, overweight humans.
Gaullier JM, Halse J, Høye K, Kristiansen K, Fagertun H, Vik H, Gudmundsen O. Gaullier JM, et al. Among authors: halse j. J Nutr. 2005 Apr;135(4):778-84. doi: 10.1093/jn/135.4.778. J Nutr. 2005. PMID: 15795434 Free article. Clinical Trial.
It confirms also that CLA decreases BFM in overweight humans, and may help maintain initial reductions in BFM and weight in the long term....
It confirms also that CLA decreases BFM in overweight humans, and may help maintain initial reductions in BFM and weight in the long term …
Incidence of vertebral deformities in 255 female rheumatoid arthritis patients measured by morphometric X-ray absorptiometry.
Orstavik RE, Haugeberg G, Uhlig T, Mowinckel P, Falch JA, Halse JI, Kvien TK. Orstavik RE, et al. Among authors: halse ji. Osteoporos Int. 2005 Jan;16(1):35-42. doi: 10.1007/s00198-004-1631-4. Epub 2004 Jun 12. Osteoporos Int. 2005. PMID: 15197538
MXA scans were analyzed pairwise by the same trained technician, and incident deformities calculated applying LSC with a 99.9% and 99.99% confidence limit, and a fixed reduction of 20% and 25% for anterior, middle or posterior heights. Long term precision (%CV) of height m …
MXA scans were analyzed pairwise by the same trained technician, and incident deformities calculated applying LSC with a 99.9% and 99.99% co …
Conjugated linoleic acid supplementation for 1 y reduces body fat mass in healthy overweight humans.
Gaullier JM, Halse J, Høye K, Kristiansen K, Fagertun H, Vik H, Gudmundsen O. Gaullier JM, et al. Among authors: halse j. Am J Clin Nutr. 2004 Jun;79(6):1118-25. doi: 10.1093/ajcn/79.6.1118. Am J Clin Nutr. 2004. PMID: 15159244 Free article. Clinical Trial.
BACKGROUND: Short-term trials showed that conjugated linoleic acid (CLA) may reduce body fat mass (BFM) and increase lean body mass (LBM), but the long-term effect of CLA was not examined. ...Adverse events did not differ significantly between groups. CONCLUSION: Lo …
BACKGROUND: Short-term trials showed that conjugated linoleic acid (CLA) may reduce body fat mass (BFM) and increase lean body mass ( …
Bone mineral density in females after jejunoileal bypass: a 25-year follow-up study.
Våge V, Gjesdal CG, Eide GE, Halse JI, Viste A. Våge V, et al. Among authors: halse ji. Obes Surg. 2004 Mar;14(3):305-12. doi: 10.1381/096089204322917792. Obes Surg. 2004. PMID: 15072648
BACKGROUND: Jejunoileal (JI) bypass was a widely performed operation for morbid obesity in the 1970s. The aim of this study was to investigate the long-term status of bone mineral density (BMD) after weight loss induced by this technique. ...
BACKGROUND: Jejunoileal (JI) bypass was a widely performed operation for morbid obesity in the 1970s. The aim of this study was to investiga …
Vertebral deformities in rheumatoid arthritis: a comparison with population-based controls.
Ørstavik RE, Haugeberg G, Mowinckel P, Høiseth A, Uhlig T, Falch JA, Halse JI, McCloskey E, Kvien TK. Ørstavik RE, et al. Among authors: halse ji. Arch Intern Med. 2004 Feb 23;164(4):420-5. doi: 10.1001/archinte.164.4.420. Arch Intern Med. 2004. PMID: 14980993
In Poisson regression analysis, vertebral deformities were independently associated with RA, BMD, and long-term corticosteroid use. CONCLUSIONS: Vertebral deformities are markedly increased in patients with RA compared with controls, especially regarding severe and multipl …
In Poisson regression analysis, vertebral deformities were independently associated with RA, BMD, and long-term corticosteroid use. C …
Vertebral deformities in 229 female patients with rheumatoid arthritis: associations with clinical variables and bone mineral density.
Ørstavik RE, Haugeberg G, Uhlig T, Falch JA, Halse JI, Høiseth A, Lilleås F, Kvien TK. Ørstavik RE, et al. Among authors: halse ji. Arthritis Rheum. 2003 Jun 15;49(3):355-60. doi: 10.1002/art.11118. Arthritis Rheum. 2003. PMID: 12794791 Free article.
The occurrence of vertebral deformities was independently associated with age, long-term corticosteroid use, and previous nonvertebral fracture, as well as reduced BMD. ...
The occurrence of vertebral deformities was independently associated with age, long-term corticosteroid use, and previous nonvertebra …
Sandostatin LAR in acromegalic patients: long-term treatment.
Fløgstad AK, Halse J, Bakke S, Lancranjan I, Marbach P, Bruns C, Jervell J. Fløgstad AK, et al. Among authors: halse j. J Clin Endocrinol Metab. 1997 Jan;82(1):23-8. doi: 10.1210/jcem.82.1.3572. J Clin Endocrinol Metab. 1997. PMID: 8989226
We have evaluated the long term effects and safety of Sandostatin LAR, a long acting formulation of octreotide, during 18 subsequent injections given every fourth week to 14 octreotide-sensitive acromegalic patients. ...One patient developed asymptomatic gallstones, and an …
We have evaluated the long term effects and safety of Sandostatin LAR, a long acting formulation of octreotide, during 18 subsequent …
15 results